Characterization of Disease Related Changes in Inflammatory Bowel Disease Using Fecal Metabolite Profiling
NCT ID: NCT01666717
Last Updated: 2012-08-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
204 participants
OBSERVATIONAL
2008-08-31
2012-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Remote Monitoring of IBD
NCT05886322
Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease
NCT03376230
Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome)
NCT02421705
Immunological Profiles in Inflammatory Bowel Disease
NCT03366090
Diet and Disease Activity in Patients With Inflammatory Bowel Disease
NCT01756963
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy controls (HC)
HC
No interventions assigned to this group
Inflammatory Bowel Disease (IBD) patients
Crohn's disease (CD), Ulcerative colitis (UC) and pouchitis
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>18 years
Exclusion Criteria
* Intake of pre- or probiotics
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kristin Verbeke
Professor K. Verbeke
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
KULeuven-UZLeuven
Leuven, Vlaams-Brabant, Belgium
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
De Preter V, Machiels K, Joossens M, Arijs I, Matthys C, Vermeire S, Rutgeerts P, Verbeke K. Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD. Gut. 2015 Mar;64(3):447-58. doi: 10.1136/gutjnl-2013-306423. Epub 2014 May 8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML4355_VOC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.